Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This study will assess safety and feasibility of infusing genetically modified autologous T
cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen
Cluster of Differentiation 19 (CD19)